Update in lung cancer 2014

Avrum Spira, Balazs Halmos, Charles A. Powell

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.

Original languageEnglish (US)
Pages (from-to)283-294
Number of pages12
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume192
Issue number3
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Lung Neoplasms
Molecular Targeted Therapy
Early Detection of Cancer
Research
Immunotherapy
Cause of Death
Neoplasms
Thorax
Tomography
Lung
Population

Keywords

  • Biomarkers
  • Chest computed tomography screening
  • Lung cancer
  • Lung immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Update in lung cancer 2014. / Spira, Avrum; Halmos, Balazs; Powell, Charles A.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 192, No. 3, 01.08.2015, p. 283-294.

Research output: Contribution to journalArticle

Spira, Avrum ; Halmos, Balazs ; Powell, Charles A. / Update in lung cancer 2014. In: American Journal of Respiratory and Critical Care Medicine. 2015 ; Vol. 192, No. 3. pp. 283-294.
@article{a0fd8b792798421b94d6ed0d7957aae4,
title = "Update in lung cancer 2014",
abstract = "In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.",
keywords = "Biomarkers, Chest computed tomography screening, Lung cancer, Lung immunotherapy, Targeted therapy",
author = "Avrum Spira and Balazs Halmos and Powell, {Charles A.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1164/rccm.201504-0756UP",
language = "English (US)",
volume = "192",
pages = "283--294",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Update in lung cancer 2014

AU - Spira, Avrum

AU - Halmos, Balazs

AU - Powell, Charles A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.

AB - In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.

KW - Biomarkers

KW - Chest computed tomography screening

KW - Lung cancer

KW - Lung immunotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84938862970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938862970&partnerID=8YFLogxK

U2 - 10.1164/rccm.201504-0756UP

DO - 10.1164/rccm.201504-0756UP

M3 - Article

C2 - 26230235

AN - SCOPUS:84938862970

VL - 192

SP - 283

EP - 294

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -